Phase 4 trials may reveal different side effects in populations without the specific condition for which the drug was originally approved.

“given the size and the number of these studies you're also looking for hey is there another side effect here that we've missed in the phase three right and it might be the the particular population that might have a different risk profile so that you might you might have a different threshold that's right because you're not doing this in patients with type 2 diabetes you're doing this in patients who explicitly don't have diabetes but have obesity ah you know different patients can are we going to see something different here”